Neurocrine Biosciences Inc (NBIX) is a publicly traded Healthcare sector company. As of July 13, 2026, NBIX trades at $177.62 with a market cap of $17.81B and a P/E ratio of 26.56. NBIX moved +0.29% today. Year to date, NBIX is +25.65%; over the trailing twelve months it is +31.27%. Its 52-week range spans $84.23 to $181.18. Analyst consensus is strong buy with an average price target of $199.11. Rallies surfaces NBIX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Neurocrine Biosciences Inc (NBIX) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. NBIX moved +0.29% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $177.62 |
| Market Cap | $17.81B |
| P/E Ratio | 26.56 |
| EPS | $6.71 |
| Dividend Yield | 0.00% |
| 52-Week High | $181.18 |
| 52-Week Low | $84.23 |
| Volume | 273 |
| Avg Volume | 0 |
| Revenue (TTM) | $3.10B |
| Net Income | $668.60M |
| Gross Margin | 98.17% |
22 analysts cover NBIX: 0 strong buy, 19 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $199.11.